JThaddeusBeckMDFACP

Oncology • Fayetteville, AR

Breast Cancer, Gynecologic Cancer, Head & Neck Cancer, Neuro-Oncology

Medical Director Research

Join to view full profile

Dr. Beck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Beck's full profile

Already have an account?

Office
3232 N Northhills Blvd
Fayetteville, AR 72703
Phone+1 479-587-1700

Fax+1 479-587-1366
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1988 - 1991
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1985 - 1988
University of Arkansas For Medical Sciences College of MedicineClass of 1985

Certifications & Licensure

AR State Medical License 1985 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

Clinical Trials

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients Start of enrollment: 2007 Apr 01
Completed
Phase 1
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy Start of enrollment: 2006 Sep 01
Terminated
Phase 2
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2011 Mar 22
Terminated
Phase 1
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 16
Completed
Phase 3
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy Start of enrollment: 2013 Oct 28
Terminated
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05
Completed
Phase 1
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Vaccination of High Risk Breast Cancer Patients Start of enrollment: 2015 Jan 14
Completed
Phase 1, Phase 2
RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
Completed
Phase 1, Phase 2
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) Start of enrollment: 2015 Aug 10
Completed
Phase 2
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Start of enrollment: 2015 Jul 23
Completed
Phase 3
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Start of enrollment: 2015 Dec 21
Completed
Phase 3
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Start of enrollment: 2016 Apr 27
Completed
Phase 2
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Start of enrollment: 2016 Jun 29
Terminated
Phase 1
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Start of enrollment: 2016 May 19
Terminated
Phase 3
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Start of enrollment: 2016 Jun 14
Completed
Phase 1, Phase 2
Vaccination of Triple Negative Breast Cancer Patients Start of enrollment: 2019 Jan 25
Completed
Phase 1, Phase 2
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Start of enrollment: 2016 Nov 28
Terminated
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Start of enrollment: 2017 Jan 16
Completed
Phase 4
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Start of enrollment: 2020 Jul 16
Active, not recruiting
Phase 3
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Increased Utilization of Low-Dose CT for Lung Cancer Screening at an Arkansas Community Oncology Clinic.
Edgar T Ellis, Michael A Bauer, J Thaddeus Beck, Daniel S Bradford, Joanna Thompson, Abby Holt, Margarete C Kulik, Shelbie D Stahr, Ping-Ching Hsu, L Joseph Su> ;Journal of the American College of Radiology. 2023 Nov 19
2 citations
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
P Neven, P A Fasching, S Chia, G Jerusalem, M De Laurentiis, S-A Im, K Petrakova, G V Bianchi, M Martín, A Nusch, G S Sonke, L De la Cruz-Merino, J T Beck, J P Zarate,...> ;Breast Cancer Research. 2023 Aug 31
2 citations
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Joanne L Blum, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, ...> ;The Oncologist. 2023 Oct 3
5 citations
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced S...
Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, J Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V Tinker, Esteban Rodrigo Imedio,...> ;Targeted Oncology. 2023 Jul 1
21 citations
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Timothy A Yap, Aditya Bardia, Michael Dvorkin, Matthew D Galsky, J Thaddeus Beck, David R Wise, Oleg Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Rohrberg, An...> ;JAMA Oncology. 2023 Jan 1
14 citations
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
Hope S Rugo, Peter Kabos, J Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J Chisamore, Sonya C Chapman, Anwar M Hossain, Yanyun Chen...> ;NPJ Breast Cancer. 2022 Nov 5
12 citations
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly dia...
Patrick Y. Wen, Jordi Rodon, Warren P. Mason, JT Beck, John DeGroot, Valerie Donnet, David Mills, Mona El-Hashimy, Mark Rosenthal> ;ESMO Open. 2020 Jul 1
6 citations
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
6 citations
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L Bajor, Patricia Cruz, J Th...> ;Clinical Lung Cancer. 2022 Nov 1
2 citations
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEES...
Guy Jerusalem, Thomas E Delea, Migule Martin, Michelino De Laurentiis, Arnd Nusch, J Thaddeus Beck, Arlene Chan, Seock-Ah Im, Patrick Neven, Alexander Lonshteyn, David...> ;Clinical Breast Cancer. 2022 Jun 1
5 citations
P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses.
Issam Makhoul, Saddam Mohammed Ibrahim, Muhammad Abu-Rmaileh, Fariba Jousheghany, Eric R. Siegel, Lora J. Rogers, John J Lee, Sergio Pina-Oviedo, Ginell R. Post, J. Th...> ;Oncotarget. 2021 Oct 26
14 citations
A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael López, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung Bae Kim, Ava Kwong, Guenther G. Steger, Esth...> ;Clinical Cancer Research. 2021 Oct 6
18 citations
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study.
Jean-Louis Pujol, Johan Vansteenkiste, Luis Paz-Ares Rodríguez, Vanesa Gregorc, Julien Mazieres, Mark M. Awad, Pasi A. Jänne, Michael Chisamore, Anwar Hossain, Yanyun ...> ;JTO Clinical and Research Reports. 2021 Sep 25
27 citations
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock-Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. H...> ;British Journal of Cancer. 2021 Aug 31
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast ...
D J Slamon, P Neven, S Chia, G Jerusalem, M De Laurentiis, S Im, K Petrakova, G Valeria Bianchi, M Martín, A Nusch, G S Sonke, L De la Cruz-Merino, J T Beck, Y Ji, C W...> ;Annals of Oncology. 2021 Oct 1
10 citations
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three...
Maen A. Hussein, Marina Maglakelidze, Donald A. Richards, Marielle Sabatini, Todd A Gersten, Keith Lerro, Ivan Sinielnikov, Alexander I. Spira, Yili Pritchett, Joyce M...> ;Cancer Management and Research. 2021 Aug 9
111 citations
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the ph...
Dennis J. Slamon, Patrick Neven, S Chia, Guy Jerusalem, M. De Laurentiis, S-A. Im, K. Petrakova, G. Valeria Bianchi, Miguel Martin, Arnd Nusch, Gabe S. Sonke, L. de la...> ;Annals of Oncology. 2021 Aug 1
16 citations
Alpelisib in combination with everolimus ± exemestane in solid tumours : Phase Ib randomised, open-label, multicentre study
Giuseppe Curigliano, Miguel Martín, Komal Jhaveri, JT Beck, Giampaolo Tortora, Nicola Fazio, Michela Maur, Richard A Hubner, Harald Lahner, Valerie Donnet, Olga Ajipa,...> ;European Journal of Cancer. 2021 May 5
13 citations
The use of patient-reported outcome measures in phase i oncology clinical trials
Robert L. Coleman, J. Thaddeus Beck, Joaquina Baranda, Ira Jacobs, Karen E. Smoyer, Lauren J Lee, Zemfira Askerova, J. McGinnis, Apar Kishor Ganti> ;Oncology. 2021 Apr 6
10 citations
A phase Ib/II study of pepinemab in combination with avelumab in advanced non–small cell lung cancer
Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest S. Smith, Vikas Mishra, Andreas Schröder, Kevin M. ...> ;Clinical Cancer Research. 2021 Jul 1
7 citations
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Sara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, Alison Conlin, E Claire Dees, Shannon L Puhalla, Brent N Rexer, Howard A Burris, Komal Jhaveri, Teresa Helsten, Car...> ;Frontiers in Oncology. 2021 Jan 1
64 citations
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart, Renata Ferrarotto, Z. Andric, J. Thaddeus Beck, Janakiraman Subramanian, Davorin Radosavljevic, Bojan Zaric, Wahid Hanna, Raid Aljumaily, Taofeek K. Ow...> ;Advances in Therapy. 2021 Jan 1
24 citations
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia Bianchi, Miguel Martin...> ;Breast. 2020 Dec 1
1 citations
Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study.
Cinthia Violeta Hernandez Puente, Ping-Ching Hsu, Lora J. Rogers, Fariba Jousheghany, Eric R. Siegel, Susan Kadlubar, J Thaddeus Beck, Issam Makhoul, Laura F. Hutchins...> ;Frontiers in Oncology. 2020 Jun 5
29 citations
Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center.
J. Thaddeus Beck, Melissa Rammage, Gretchen Purcell Jackson, Anita M. Preininger, Irene Dankwa-Mullan, M Christopher Roebuck, Adam Torres, Helen Holtzen, Sadie Coverdi...> ;JCO Clinical Cancer Informatics. 2020 Jan 24
Join now to see all